Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
BOOST-3 clinical trial aims to improve outcomes for severe TBI patients

BOOST-3 clinical trial aims to improve outcomes for severe TBI patients

An estimated 2.5 million Americans sustain a traumatic brain injury, or TBI, each year, according to the Centers for Disease Control and Prevention. Severe TBI contributes to 30 percent of all injury-related deaths, and many who survive are left permanently disabled.

“Of the nearly 300,000 hospital admissions annually for TBI, about 40 percent are classified as severe,” says William Barsan, M.D., a professor of emergency medicine at Michigan Medicine.

“Unfortunately, less than 20 percent of patients with a severe TBI make a good recovery -; and many are left with lifelong disabilities and medical needs.”

Barsan is one of the principal investigators of an ongoing emergency department clinical trial, Brain Oxygen Optimization in Severe TBI, Phase 3 (BOOST-3), which aims to improve outcomes for severe TBI patients.

In addition to Barsan, primary investigators for the BOOST-3 trial are Ramon Diaz-Arrastia, M.D., Ph.D., director of the Traumatic Brain Injury Clinical Research Center in the Perelman School of Medicine at the University of Pennsylvania; Lori Shutter, M.D., professor of critical care medicine, neurology and neurosurgery at the University of Pittsburgh and medical director of neurointensive care units at the University of Pittsburgh Medical Center; and Sharon Yeatts, Ph.D., associate professor of biostatistics at the Medical University of South Carolina.

Severe TBI patients in the intensive care unit have been managed by monitoring intracranial pressure and treating the elevated pressure to prevent secondary injury, Barsan notes.

But recent clinical trial data have shown that this approach may not be enough.

“New trials are showing that monitoring the partial pressure of oxygen in brain tissue allows for more timely interventions,” Barsan says. “Because of this, many physicians have started measuring brain oxygen in these patients as part of standard practice. It is unknown if this strategy, which requires an additional procedure, is better, worse or the same as the traditional approach.”

That’s why Barsan, Diaz-Arrastia, Shutter and Yeatts designed the BOOST-3 trial.

This $32 million trial will be conducted in the National Institutes of Health-funded Strategies to Innovate Emergency Care Clinical Trials Network (SIREN). Michigan Medicine is the clinical coordinating center for the network.

Building on prior research

Diaz-Arrastia and Shutter conducted the trial’s second phase, BOOST-2, which was published in 2017. That trial hypothesized that treating patients based on measurements of both intracranial pressure and brain oxygen levels would reduce the duration and severity of periods in which brain tissue oxygen levels were low in patients with TBI compared with treatment of intracranial pressure alone.

The team explained that low levels of brain tissue oxygen can cause further loss of brain cells or prevent their recovery. Knowing about both pressure and oxygen in the brain may provide critical care doctors the clues they need to precisely adjust medications and breathing machine settings for patients.

“We found that brain hypoxia burden was reduced by 74 percent in the patients monitored and treated based on partial pressure of oxygen in brain tissue and intracranial pressure monitoring compared to intracranial pressure monitoring alone,” Shutter says. “We’re now building upon the data we collected in the BOOST-2 trial and moving onto this third phase, where we will expand our hypothesis.”

That new hypothesis: Treating TBI based on partial pressure of oxygen in the brain tissue and intracranial pressure monitoring will improve neurological outcomes six months after the injury compared with treatment based on intracranial pressure monitoring alone.

“It’s important to consider the long-term survival and health of patients with TBI,” Shutter says. “This phase of the trial will show whether we can improve long-term outcome with this treatment strategy.”

A coordinated effort

BOOST-3 will begin in 2018 at 45 SIREN clinical sites across the United States and will continue for five years.

It plans to enroll 1,094 participants with severe TBI. Subjects will be randomized within six hours of arriving at an enrolling hospital, but no longer than 12 hours from injury.

All patients will have brain tissue oxygen monitors and intracranial pressure monitors placed within six hours of arrival at the hospital. Patients will then be randomized to treatment based on intracranial pressure alone or treatment based on both intracranial pressure and brain tissue oxygen levels for the first five days after admission, with all other care being standard.

Subjects will be followed for six months, and investigators will compare the functional outcomes and neurological function of the two groups.

SIREN seeks to improve the outcomes of patients with neurologic, cardiac, respiratory, hematologic and trauma emergencies by identifying effective treatments administered in the earliest stages of critical care and is supported by the National Institute for Neurological Disorders and Stroke (NINDS) and the National Heart, Lung and Blood Institute (NHLBI). Beyond Michigan Medicine, the network includes a data coordinating center at the Medical University of South Carolina and 11 award hubs with primary investigators at each.

“Improving the recovery of patients with severe brain injury is an important priority at the NIH,” says Jeremy Brown, M.D., the NINDS medical officer who works with the SIREN team. “The results of this trial will provide important information which doctors and nurses around the country will then use to benefit the patients in their care.”

Excitement for the collaborative approach on the study is shared across institutions.

“The SIREN data coordinating center at the Medical University of South Carolina could not be more excited about helping to lead this effort to improve the care of severe TBI patients,” Yeatts says. “My team at MUSC has been collaborating with TBI experts across the country on various trials, and we now have the opportunity to help to inform health care providers of best treatment approaches so patients all over the country will have better outcomes.

“Regardless of the results, this study will have a dramatic impact, and we are proud to be a part of it.”

Barsan, Diaz-Arrastia, Shutter and Yeatts hope this phase of the trial will build upon the findings from BOOST-2.

“We truly hope this clinical trial will provide emergency, neurosurgery and critical care physicians with improved treatment protocols for severe TBI going forward,” Barsan says. “Our main goal is to improve long-term outcome and improved quality of life after severe TBI through the results of the BOOST-3 trial.”

Source:

https://labblog.uofmhealth.org/industry-dx/boost-3-trial-seeks-to-improve-outcomes-after-severe-traumatic-brain-injury

Tagged with:

About author

Related Articles